Owlstone Medical secures $49.1 million ARPA-H award
Cambridge-based breath diagnostics specialist Owlstone Medical has been awarded up to $49.1 million by ARPA-H to develop at-home multi-cancer early detection tests. The POSEIDON programme aims to detect 30+ solid tumours at Stage I using synthetic biosensors analysed through breath and urine samples, addressing critical gaps in accessible cancer screening.
